This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is a biotech company that was founded in 2008 and is developing a new drug candidate for the treatment of advanced colorectal cancer. Colorectal cancer (CRC) is the third most common form of cancer worldwide and the need for more effective drugs to treat this disease is very high.
MEET OUR NEW
Chairman of the Board
Jan Törnell
MEDIA - Latest press releases
Upcoming Events
- August 23, 2022 - August 23, 2022
Interim Report Q2 2022 - August 31, 2022 - August 31, 2022
Redeye Late Stage Life Science conference 2022 - September 07, 2022 - September 08, 2022
Pareto Securities' 13th annual Healthcare Conference 2022, Stockholm
Isofol will attend the conference and CEO, Ulf Jungnelius, will give a presentation on September 7 at 14:30 CEST.
